LXP1788

This product, LXP1788, is a new ingredient and new drug. It is a multi-target tyrosine kinase inhibitor, among which the inhibitory effect on AURKA is the most obvious. It has been approved by the United States, Taiwan, the European Union (11 countries have been designated), China (including Hong Kong and Macau), South Korea, and other countries patents. Its advantage is that it can simultaneously inhibit multiple signal transmission pathways necessary for cancer cell proliferation, and can inhibit the growth of tumor cells more effectively than single-target drugs.